左西孟旦治疗失代偿性心力衰竭患者的临床疗效观察  

The clinical effects of levosimendan in treatment of decompensated heart failure

作　　者：杨延民[1] 孙志桂[1] 许传祥 

机构地区：[1]山东省日照市人民医院心内科,山东日照276821 [2]山东省日照市东港区陈疃卫生院,山东日照276819

出　　处：《中国现代医生》2014年第9期52-53,56,共3页China Modern Doctor

摘　　要：目的探讨左西孟旦治疗失代偿性心力衰竭患者的临床效果。方法 70例失代偿性心衰患者随机分为对照组与观察组各35例。两组均予基础治疗,对照组在此基础上给予盐酸多巴酚丁胺治疗,观察组予左西孟旦治疗。比较两组的疗效、治疗前后B型脑钠肽(BNP)、左室射血分数(LVEF)、每搏心输出量(SVI)及不良反应。结果对照组临床治疗总有效率68.57%(24/35),观察组94.29%(33/35)(P<0.05);观察组治疗后BNP、LVEF及SVI较对照组有显著性差异(P<0.05);对照组不良反应发生率为17.14%(6/35),观察组为5.71%(2/35),两组比较差异显著(P<0.05)。结论左西孟旦治疗失代偿性心力衰竭患者的临床效果显著,安全性高,应在临床上加以推广。Objective To investigate the clinical effects of levosimendan in treatment of decompensated heart failure. Methods Seventy cases were randomly divided into control group and observation group, 35 cases in each group. Both groups were given basic treatment, the control group received dobutamine hydrochloride, the observation group was treated with levosimendan treatment. Clinical efficacy, BNP, LVEF, SVI of：before and after the treatment and adverse reactions were compared. Results The clinical total effective rate of control ~group was 68.57%（24/35）, and that of ob- servation group was 94.29%（33/35）（P 〈 0.05）; BNP, LVEF and SVI of observation group were compared with the control group, the difference were statistically significant（P 〈 0.05）; Incidence of adverse reactions of control group was 17.14% （6/35）, and that of the observation group was 5.71%（2/35）（P 〈 0.05）. Conclusion The clinical effect of levosimendan in treatment of decompensated heart failure is exact, safe, and should be the promotion and popularization.

关 键 词：左西孟旦 失代偿性心衰 不良反应 

分 类 号：R541.6[医药卫生—心血管疾病]